Amy Carter, MD
Family Medicine · Brownsboro, ALNPI 1063464501
Payments from drug & device makers
Across 693 payments — averaging $13.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Pfizer$845
- Lilly USA, LLC$777
- GSK$696
- AstraZeneca$575
- AbbVie$505
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,987100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 261 | $2,158 |
| Pfizer | 56 | $845 |
| Lilly USA, LLC | 50 | $777 |
| GSK | 40 | $696 |
| AstraZeneca | 42 | $575 |
| AbbVie(2 entities) | 28 | $505 |
| Boehringer Ingelheim | 20 | $331 |
| Amgen | 18 | $310 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $297 |
| Johnson & Johnson(2 entities) | 20 | $294 |
| Merck | 17 | $289 |
| Lundbeck LLC | 12 | $273 |
| Phathom Pharmaceuticals, Inc. | 26 | $233 |
| Bayer | 10 | $199 |
| Amarin Pharma, Inc. | 10 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $166 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $149 |
| Abbott | 7 | $136 |
| Eisai Inc. | 9 | $129 |
| Esperion Therapeutics, Inc. | 5 | $84 |
| Biohaven Pharmaceuticals, Inc. | 3 | $62 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Philips North America LLC | 2 | $31 |
| Bioventus LLC | 1 | $23 |
| IBSA Pharma Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$144
How this compares
$9,012 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $110,330 |
| EliquisApixaban | 68 | $78,248 |
| MounjaroTirzepatide | 43 | $55,420 |
| RybelsusSemaglutide | 28 | $48,671 |
| JardianceEmpagliflozin | 30 | $47,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $34,656 |
| XareltoRivaroxaban | 25 | $30,556 |
| FarxigaDapagliflozin Propanediol | 25 | $24,406 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $18,007 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 41 | $12,962 |
| Repatha SureclickEvolocumab | 14 | $10,619 |
| OxycontinOxycodone Hcl | 12 | $10,503 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,269 |
| JanuviaSitagliptin Phosphate | 12 | $10,023 |
| BelsomraSuvorexant | 21 | $9,860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,158 | $159,002108 claims |
| PfizerEliquis, Paxlovid | $845 | $80,97279 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $696 | $56,509119 claims |
| Lilly USA, LLCMounjaro | $777 | $55,42043 claims |
| Boehringer IngelheimJardiance | $331 | $47,49930 claims |
| Johnson & JohnsonXarelto | $294 | $30,55625 claims |
| AstraZenecaFarxiga | $575 | $24,40625 claims |
| MerckJanuvia, Belsomra | $289 | $19,88433 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $17 | $10,26912 claims |
| AbbVieSynthroid | $505 | $1,43119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Brownsboro
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.